History of Changes for Study: NCT02526524
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
Latest version (submitted March 27, 2018) on
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 August 17, 2015 None (earliest Version on record)
2 September 26, 2015 Recruitment Status, Contacts/Locations, Study Status and Oversight
3 October 30, 2015 Study Status and Eligibility
4 November 19, 2015 Contacts/Locations and Study Status
5 November 25, 2015 Contacts/Locations and Study Status
6 December 13, 2015 Contacts/Locations, Study Status and Eligibility
7 December 30, 2015 Contacts/Locations and Study Status
8 January 7, 2016 Study Status and Contacts/Locations
9 March 2, 2016 Contacts/Locations and Study Status
10 May 10, 2016 Recruitment Status, Contacts/Locations and Study Status
11 November 22, 2016 Recruitment Status, Study Status and Contacts/Locations
12 December 12, 2016 Study Status
13 January 4, 2017 Study Design and Study Status
14 March 27, 2018 Study Status, Results and Contacts/Locations
Comparison Format:

Scroll up to access the controls

Study NCT02526524
Submitted Date:  December 30, 2015 (v7)

Open or close this module Study Identification
Unique Protocol ID: LCRM112
Brief Title: Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
Official Title: Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled, Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release In Subjects With Type 2 Diabetes Mellitus
Secondary IDs:
Open or close this module Study Status
Record Verification: December 2015
Overall Status: Recruiting
Study Start: September 2015
Primary Completion: July 2016 [Anticipated]
Study Completion:
First Submitted: August 16, 2015
First Submitted that
Met QC Criteria:
August 17, 2015
First Posted: August 18, 2015 [Estimate]
Last Update Submitted that
Met QC Criteria:
December 30, 2015
Last Update Posted: January 1, 2016 [Estimate]
Open or close this module Sponsor/Collaborators
Sponsor: Elcelyx Therapeutics, Inc.
Responsible Party: Sponsor
Open or close this module Oversight
U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring: No
Open or close this module Study Description
Brief Summary: The purpose of the study is to compare the glycemic effects of delayed-release metformin (Met DR) to placebo in subjects with type 2 diabetes mellitus (T2DM) over 16 weeks. The study is designed to evaluate several doses of Met DR (600 to 1500 mg once daily in the morning [qAM]) compared to placebo. A single-blind reference treatment of 2000 mg metformin immediate-release (Met IR) per day administered as equal divided doses (1000 mg Met IR BID) will also be included.
Detailed Description:
Open or close this module Conditions
Conditions: Type 2 Diabetes Mellitus
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 2
Interventional Study Model: Parallel Assignment
Number of Arms: 7
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation: Randomized
Enrollment: 552 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: 600 mg Met DR qAM
600 mg metformin delayed-release once daily in the morning
Drug: Met DR
metformin delayed-release tablets
Experimental: 900 mg Met DR qAM
900 mg metformin delayed-release once daily in the morning
Drug: Met DR
metformin delayed-release tablets
Experimental: 1200 mg Met DR qAM
1200 mg metformin delayed-release once daily in the morning
Drug: Met DR
metformin delayed-release tablets
Experimental: 1500 mg Met DR qAM
1500 mg metformin delayed-release once daily in the morning
Drug: Met DR
metformin delayed-release tablets
Placebo Comparator: Placebo-1
placebo match for 600 and 1200 mg Met DR qAM treatment groups
Drug: Placebo
Placebo Comparator: Placebo-2
placebo match for 900 and 1500 mg Met DR qAM treatment groups
Drug: Placebo
Active Comparator: 2000 mg Met IR
1000 mg metformin immediate-release twice daily
Drug: Met IR
metformin immediate-release tablets
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Change in HbA1c (%) at 16 Weeks
[ Time Frame: Baseline and 16 weeks after the first dose of study medication ]

Open or close this module Eligibility
Minimum Age: 25 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No

Inclusion Criteria:

  1. Is at least 25 years old at Visit 1 (Screening).
  2. Is male, or is female and meets all of the following criteria:
    1. Not breastfeeding
    2. Negative pregnancy test result at Visit 1 (not applicable to post-menopausal or surgically sterile females)
    3. Surgically sterile, postmenopausal, or if of childbearing potential, must practice and be willing to continue to practice appropriate birth control during the entire duration of the study.
  3. Body mass index (BMI) 20.0 to 45.0 kg/m² (inclusive) at Visit 1 (Screening).
  4. Has a physical examination with no clinically significant abnormalities as judged by the investigator.
  5. Has T2DM and an HbA1c of 7.5% to 10.5%, inclusive, at Visit 1.
  6. Has an estimated glomerular filtration rate (eGFR) value of ≥60 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation.
  7. Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 3 months prior to Visit 1:
    1. Thiazolidinedione, sulfonylurea, dipeptidyl peptidase-4 inhibitors, and alpha-glucosidase inhibitors
    2. Hormone replacement therapy (female subjects) and testosterone (male subjects)
    3. Oral contraceptives (female subjects)
    4. Antihypertensive agents
    5. Lipid-lowering agents
    6. Thyroid replacement therapy
    7. Antidepressant agents
  8. Ability to understand and willingness to adhere to protocol requirements.

Exclusion Criteria:

  1. Has a clinically significant medical condition as judged by the investigator that could potentially affect study participation and/or personal well-being, including but not limited to the following conditions:
    1. Hepatic disease
    2. Gastrointestinal disease
    3. Endocrine disorder (T2DM is allowed)
    4. Cardiovascular disease
    5. Central nervous system diseases
    6. Psychiatric or neurological disorders
    7. Organ transplantation
    8. Chronic or acute infection
    9. Orthostatic hypotension, fainting spells or blackouts
    10. Allergy or hypersensitivity.
  2. A history of diabetic ketoacidosis or hyperosmolar non-ketotic hyperglycemia within the past year.
  3. Prior major surgery of any kind within 6 months of Visit 1.
  4. A history of >3% weight change within 3 months of Visit 1.
  5. A clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormality, other than that related to T2DM, judged by the investigator to be clinically significant at Visit 1.
  6. An alanine aminotransferase or aspartate aminotransferase result >2.5 × upper limit of normal (ULN) or a bilirubin result >1.5 × ULN.
  7. A physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study.
  8. Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following excluded medications:
    1. Metformin within 2 months of Visit 1 (Screening)
    2. Insulin within 2 weeks of Visit 1 (Screening) or for more than 1 week within 3 months of Visit 1 (Screening)
    3. Glucagon-like peptide-1 receptor agonists or sodium-glucose co-transporter 2 inhibitors within 3 months of Visit 1
    4. Drugs known to affect body weight, including prescription medications and over-the-counter anti obesity agents within 3 months of Visit 1.
    5. Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption within 3 months of Visit 1
    6. Planned use of any drug treatment that affects gastric pH (prescription or over-the-counter), such as H2-receptor antagonists and proton pump inhibitors, after Visit 2 (Week -2), or planned chronic use of any antacids (i.e., more than twice per week) after Visit 2 (Week -2)
    7. Cationic drugs that are eliminated by renal tubular secretion within 1 week of Visit 1.
    8. Iodinated contrast dye within 1 week prior to Visit 1.
    9. Investigational drug within 2 months (or five half-lives of the investigational drug, whichever is greater) of the date of the first dose of randomized study medication.
    10. Met DR or double-blind matching placebo for Met DR at any time prior to Visit 1 (Screening)
  9. Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures.
  10. Had a blood transfusion or experienced significant blood loss (i.e., >500 mL), including loss due to blood donation, within 2 months prior to Visit 1 (Screening), or is planning to donate blood during the study.
  11. Has known immune system based allergies or hypersensitivity to any component of study treatment. A history of gastrointestinal intolerance to metformin is not exclusionary.
  12. Is employed by Elcelyx Therapeutics, Inc. (that is an employee, contract worker, or designee of the company).
  13. Has a fasting plasma glucose value >270 mg/dL at Visit 1 (Screening), Visit 2 (Week -2), and an unscheduled visit to be completed within 1 week following Visit 2. The unscheduled visit is to be completed only for subjects with a fasting plasma glucose value >270 mg/dL at Visit 1 and Visit 2.
Open or close this module Contacts/Locations
Central Contact Person: Dismas Meyers
Telephone: 513-579-9911 Ext. 2676
Study Officials: Juan P Frias, MD
Principal Investigator
National Research Institute - Wilshire
Locations: United States, Alabama
Pinnacle Research Group, LLC
Anniston, Alabama, United States, 36207
Contact:Principal Investigator: Almena L Free, MD, CCRP
Central Alabama Research
Birmingham, Alabama, United States, 35209
Contact:Principal Investigator: Barry McLean, MD
Achieve Clinical Research, LLC
Birmingham, Alabama, United States, 35216
Contact:Principal Investigator: Gary Boyd, MD
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Contact:Principal Investigator: Timothy Garvey, MD
Terence T. Hart, MD
Muscle Shoals, Alabama, United States, 35662
Contact:Principal Investigator: Terence T Hart, MD
United States, Arizona
Radiant Research - Phoenix
Chandler, Arizona, United States, 85224
Contact:Principal Investigator: Randall Severance, MD
Arrowhead Health Centers
Glendale, Arizona, United States, 85306
Contact:Principal Investigator: Janice Johnston, MD
Holland Center for Family Health, LTD
Peoria, Arizona, United States, 85381
Contact:Principal Investigator: Joshua Holland, MD
Elite Clinical Studies
Phoenix, Arizona, United States, 85018
Contact:Principal Investigator: Joseph Lillo, MD
Redpoint Research
Phoenix, Arizona, United States, 85029
Contact:Principal Investigator: Herbert Goodman, MD
Thunderbird Internal Medicine - Indian School Rd.
Phoenix, Arizona, United States, 85037
Contact:Principal Investigator: Daniel Schlosser, MD
Clinical Research Institute of Arizona, LLC
Surprise, Arizona, United States, 85374
Contact:Principal Investigator: Jalal Abbas, MD
United States, Arkansas
Summit Clinical Trials Center
Fayetteville, Arkansas, United States, 72703
Contact:Principal Investigator: Marianela Lavena, MD
Lynn Institiute of the Ozarks
Little Rock, Arkansas, United States, 72205
Contact:Principal Investigator: Chrystal Johnson, MD
Searcy Medical Center
Searcy, Arkansas, United States, 72143
Contact:Principal Investigator: David Johnson, MD
United States, California
Catalina Research Institute
Chino, California, United States, 91710
Contact:Principal Investigator: Gilbert Martinez, MD
Advanced Metabolic Care & Research Institute (AMCR)
Escondido, California, United States, 92025
Contact:Principal Investigator: Timothy Bailey, MD
MD Studies, Inc.
Fountain Valley, California, United States, 92708
Contact:Principal Investigator: Ron Schilling, MD
National Research Institute
Huntington Park, California, United States, 90255
Contact:Principal Investigator: Stanley H-W Hsia, MD, FRCPC, FACE
Scripps Whittier Diabetes Institute
La Jolla, California, United States, 92037
Contact:Principal Investigator: Athena Philis-Tsimikas, MD
Clinical Trials Research
Lincoln, California, United States, 95648
Contact:Principal Investigator: Jeffrey D Wayne, MD
Collaborative Neuroscience Network, LLC
Long Beach, California, United States, 90806
Contact:Principal Investigator: Steven Reynolds, DO
National Research Institute
Los Angeles, California, United States, 90057
Contact:Principal Investigator: Juan P Frias, MD
SRSD, Inc. dba Synergy San Diego
National City, California, United States, 91950
Contact:Principal Investigator: Frederick Jenkin, DO
Providence Clinical Research
North Hollywood, California, United States, 91606
Contact:Principal Investigator: Teresa Sligh, MD
Pacific Research Partners, LLC
Oakland, California, United States, 94612
Contact:Principal Investigator: Anand Mehta, MD
SDS Clinical Trials, Inc.
Orange, California, United States, 92868
Contact:Principal Investigator: Andrew Schreiber, MD
Center for Clinical Trials of Sacramento
Sacramento, California, United States, 95823
Contact:Principal Investigator: Rebecca Jordan, MD
Center for Clinical Trials of Scaramento
Sacramento, California, United States, 95823
Contact:Principal Investigator: Rebecca Jordan, MD
Superior Research LLC
Sacramento, California, United States, 95825
Contact:Principal Investigator: Francisco Garcia, MD
Syrentis Clinical Research (formerly Research Across America)
Santa Ana, California, United States, 92705
Contact:Principal Investigator: Nabil Charle Morcos, MD
Encompass Clinical Research
Spring Valley, California, United States, 91978
Contact:Principal Investigator: Robert S Lipetz, DO
Clinical Trial Investigators
Tustin, California, United States, 92780
Contact:Principal Investigator: Jean-Louis Selam, MD
Infosphere Clinical Research
West Hills, California, United States, 91307
Contact:Principal Investigator: Dan Streja, MD
United States, Colorado
Colorado Springs Health Partners
Colorado Springs, Colorado, United States, 80906
Contact:Principal Investigator: Kari Uusinarkaus, MD
Creekside Endocrine Associates
Denver, Colorado, United States, 80209
Contact:Principal Investigator: Leonard Zemel, MD
United States, Florida
Meridien Research - Brooksville
Brooksville, Florida, United States, 34601
Contact:Principal Investigator: Kelli Maw, MD
ALL Medical Research, LLC
Cooper City, Florida, United States, 33024
Contact:Principal Investigator: Lorena Lewy-Alterbaum, MD
Neostart Corporation dba AGA Clinical Trials
Hialeah, Florida, United States, 33012
Contact:Principal Investigator: Dario Altamirano, DO
Care Partners Clinical Research
Jacksonville, Florida, United States, 32277
Contact:Principal Investigator: Kim Barbel-Johnson, MD
Health Awareness, Inc.
Jupiter, Florida, United States, 33458
Contact:Principal Investigator: Ronald Surowitz, DO
Family Health Care Clinical Studies
Kissimmee, Florida, United States, 34741
Contact:Principal Investigator: Michael H Link, MD
Clinical Research of Central Florida-Lakeland
Lakeland, Florida, United States, 33810
Contact:Principal Investigator: Christopher Miller, MD
Clinical Pharmacology of Miami, Inc.
Miami, Florida, United States, 33014
Contact:Principal Investigator: Kenneth Lasseter, MD
Tellus Clinical Research, Inc.
Miami, Florida, United States, 33173
Contact:Principal Investigator: Martin Valdes, MD
Internal Research Associates LLC - Breton
Miami, Florida, United States, 33183
Contact:Principal Investigator: Cristian Breton, MD
Clinical Neuroscience Solutions, Inc. Healthcare Orlando
Orlando, Florida, United States, 32801
Contact:Principal Investigator: Linda Harper, MD
Ormond Medical Arts Pharmaceutical Research Center
Ormond Beach, Florida, United States, 32174
Contact:Principal Investigator: David W Carpenter, MD
Private Practice - Andres Patron, DO
Pembroke Pines, Florida, United States, 33026
Contact:Principal Investigator: Andres Patron, DO
Progressive Medical Research
Port Orange, Florida, United States, 32127
Contact:Principal Investigator: Alexander White, MD
Meridien Reserach - St. Petersburg
St. Petersburg, Florida, United States, 33709
Contact:Principal Investigator: Gigi Lefebvre, MD
Clinical Reserch Trials of Florida
Tampa, Florida, United States, 33607
Contact:Principal Investigator: Sady Alpizar, MD
Meridien Research - Tampa
Tampa, Florida, United States, 33634
Contact:Principal Investigator: Cynthia Huffman, MD
Metabolic Research Institute, Inc.
West Palm Beach, Florida, United States, 33401
Contact:Principal Investigator: Barry Horowitz, MD
United States, Georgia
Endocrine Research Solutions, Inc.
Roswell, Georgia, United States, 30076
Contact:Principal Investigator: John 'Chip' Reed, MD
United States, Illinois
Biofortis, Inc.
Addison, Illinois, United States, 60101
Contact:Principal Investigator: Kathleen Kelley, MD
AMR Sakeena Research
Aurora, Illinois, United States, 60506
Contact:Principal Investigator: Sifatur Sayeed, MD
Cedar-Crosse Research Center
Chicago, Illinois, United States, 60607
Contact:Principal Investigator: Danny Sugimoto, MD
Evanston Premier Healthcare Research LLC
Evanston, Illinois, United States, 60201
Contact:Principal Investigator: Jeffrey Geohas, MD
United States, Indiana
Buynak Clinical Research, PC
Valparaiso, Indiana, United States, 46383
Contact:Principal Investigator: Robert Buynak, MD
United States, Iowa
The Iowa Clinic; Cardiovascular Services
West Des Moines, Iowa, United States, 50266
Contact:Principal Investigator: Kathleen Jones, MD
United States, Kansas
Heartland Research Associates, LLC - Augusta
Augusta, Kansas, United States, 67010
Contact:Principal Investigator: Michael Rausch, MD
Cotton-O'Neil Clinical Research Center
Topeka, Kansas, United States, 66606
Contact:Principal Investigator: Michael Cox, MD
United States, Kentucky
Edgewood, Kentucky, United States, 41017
Contact:Principal Investigator: Pragya Gupta, MD
Kentucky Diabetes Endocrinology Center
Lexington, Kentucky, United States, 40503
Contact:Principal Investigator: Lyle Myers, MD
Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
Louisville, Kentucky, United States, 40213
Contact:Principal Investigator: Harold Bays, MD
Four Rivers Clinical Research
Paducah, Kentucky, United States, 42003
Contact:Principal Investigator: Raymond De La Rosa, MD
United States, Louisiana
Avant Research Associates
Crowley, Louisiana, United States, 70526
Contact:Principal Investigator: Satinder Saini, MD
Centex Studies, Inc. - lake Charles
Lake Charles, Louisiana, United States, 70601
Contact:Principal Investigator: Michael Seep, MD
United States, Maryland
Columbia Medical Practice
Columbia, Maryland, United States, 21045
Contact:Principal Investigator: William Saway, MD
Medstar Health Research Institute
Hyattsville, Maryland, United States, 20782
Contact:Principal Investigator: Vanita Aroda, MD
MD Medical Research
Oxon Hill, Maryland, United States, 20745
Contact:Principal Investigator: Stephen Ong, MD
United States, Massachusetts
Beacon Clinical Research
Quincy, Massachusetts, United States, 02169
Contact:Principal Investigator: Victoria Kuohung, MD
United States, Minnesota
Radiant Research - Edina
Edina, Minnesota, United States, 55435
Contact:Principal Investigator: Larry Kotek, MD
United States, Mississippi
Planters Clinic
Port Gibson, Mississippi, United States, 39150
Contact:Principal Investigator: David Headley, MD
United States, Montana
Mercury Street Medical Group, PLLC
Butte, Montana, United States, 59701
Contact:Principal Investigator: John Pullman, MD
United States, Nebraska
Quality Clinical Research, Inc.
Omaha, Nebraska, United States, 68114
Contact:Principal Investigator: Michael Dunn, MD
Heartland Clinical Research
Omaha, Nebraska, United States, 68134
Contact:Principal Investigator: Alfred Felber, MD
United States, Nevada
Alliance Against Diabetes
Las Vegas, Nevada, United States, 89101
Altea Research
Las Vegas, Nevada, United States, 89102
Contact:Principal Investigator: Jelena Kunovac, MD
AB Clinical Trials
Las Vegas, Nevada, United States, 89119
Contact:Principal Investigator: Atoya Adams, MD
Palm Medical Research
Las Vegas, Nevada, United States, 89128
Contact:Principal Investigator: Samer Nakhle, MD
Ingham Neuroscience Group LLC
Las Vegas, Nevada, United States, 89146
Contact:Principal Investigator: Maxine B Ingham, MD, MPH
Ingham Neuroscience Group, LLC
Las Vegas, Nevada, United States, 89146
Contact:Principal Investigator: Maxine Ingham, MD
United States, New Jersey
Comprehensive Clinical Research
Berlin, New Jersey, United States, 08009
Contact:Principal Investigator: David Hassman, DO
United States, New Mexico
Albuquerque Clinical Trials
Albuquerque, New Mexico, United States, 87102
Contact:Principal Investigator: Elizabeth Bretton, MD
Albuquerque Neuroscience, Inc.
Albuquerque, New Mexico, United States, 87109
Contact:Principal Investigator: Paula Lane, MD
United States, New York
NY Scientific
Brooklyn, New York, United States, 11235
Contact:Principal Investigator: Igor Grosman, DO
Long Island Gastrointestinal Research Group
Great Neck, New York, United States, 11023
Contact:Principal Investigator: Michael Goldstein, MD
Mid-Hudson Medical Research, PLLC
Hopewell Junction, New York, United States, 12533
Contact:Principal Investigator: Rabi Sinha, MD
Great Lakes Medical Research
Westfield, New York, United States, 14787
Contact:Principal Investigator: Donald Brautigam, MD
United States, North Carolina
Greensboro, North Carolina, United States, 27408
Contact:Principal Investigator: Alexander Murray, MD
Triad Clinical Trials LLC
Greensboro, North Carolina, United States, 27410
Contact:Principal Investigator: Richard Montgomery, MD
PMG Research of Rocky Mount
Rocky Mount, North Carolina, United States, 27804
Contact:Principal Investigator: Nilay Desai, MD
PMG Research of Salisbury, LLC
Salisbury, North Carolina, United States, 28144
Contact:Principal Investigator: Robert McNeill, MD
PMG Research of Wilmington, LLC
Wilmington, North Carolina, United States, 28401
Contact:Principal Investigator: Kevin Cannon, MD
United States, Ohio
Clinical Inquest Center
Beavercreek, Ohio, United States, 45432
Contact:Principal Investigator: Avni Arora, MD
Sterling Research Group, Ltd
Cincinnati, Ohio, United States, 45219
Contact:Principal Investigator: Matthew Wenker, MD
Metabolic Atherosclerosis Research Center
Cincinnati, Ohio, United States, 45227
Contact:Principal Investigator: Traci Turner, MD
New Horizons Clinical Research
Cincinnati, Ohio, United States, 45242
Contact:Principal Investigator: Gregory Gottschlich, MD
Urgent Care Specialists, LLC DBA Hometown Urgent Care and Occupational Health
Columbus, Ohio, United States, 43214
Contact:Principal Investigator: Jeffrey White, MD
Prestige Clinical Research
Franklin, Ohio, United States, 45005
Contact:Principal Investigator: Gary W Bedel, MD
Hometown Urgent Care and Research - Huber Heights
Huber Heights, Ohio, United States, 45424
Contact:Principal Investigator: Steve Choi, MD
RAS Health LTD
Marion, Ohio, United States, 43302
Contact:Principal Investigator: Sudesh Reddy, MD
Summit Reserach Group, LLC
Stow, Ohio, United States, 44224
Contact:Principal Investigator: Scott Rigby, MD
United States, Oklahoma
COR Clinical Research, LLC
Oklahoma City, Oklahoma, United States, 73103
Contact:Principal Investigator: Clinton Corder, MD
United States, Oregon
Willamette Valley Clinical Studies
Eugene, Oregon, United States, 97404
Contact:Principal Investigator: Patricia Buchanan, MD
United States, Pennsylvania
Brandywine Clinical Research
Downington, Pennsylvania, United States, 19335
Contact:Principal Investigator: Lawrence Alwine, MD
United States, South Carolina
Medical Research South, LLC
Charleston, South Carolina, United States, 29407
Contact:Principal Investigator: Donald P Hurley, DO
Mountain View Clinical Research - Greer
Greer, South Carolina, United States, 29651
Contact:Principal Investigator: Ronald Keith Mayfield, MD
Coastal Carolina Research Center, Inc.
Mount Pleasant, South Carolina, United States, 29464
PMG of Charleston, LLC
Mt. Pleasant, South Carolina, United States, 29464
Contact:Principal Investigator: Richard Mills, MD
Family Medicine of SayeBrook, LLC
Myrtle Beach, South Carolina, United States, 29588
Contact:Principal Investigator: Karen L Mahood, DO
Hillcrest Clinical Research, LLC
Simpsonville, South Carolina, United States, 29681
Contact:Principal Investigator: Robert E Broker, MD
Palmetto Proactive Healthcare, LLC
Spartanburg, South Carolina, United States, 29301
Contact:Principal Investigator: Christopher McCarthy, MD
Spartanburg Medical Research
Spartanburg, South Carolina, United States, 29303
Contact:Principal Investigator: Charles M Fogarty, MD, CPI
Palmetto Clinical Research
Summerville, South Carolina, United States, 29485
Contact:Principal Investigator: D. Eric Bolster, MD
United States, Tennessee
PMG Research of Bristol, LC - State
Bristol, Tennessee, United States, 37620
Contact:Principal Investigator: Stephanie Powell, MD
PMG Research of Knoxville
Knoxville, Tennessee, United States, 37912
Contact:Principal Investigator: Paul Wakefield, MD
Clinical Neuroscience Solutions, Inc. - Memphis
Memphis, Tennessee, United States, 38119
Contact:Principal Investigator: Lora McGill, MD
Trinity Clinical Research
Tullahoma, Tennessee, United States, 37388
Contact:Principal Investigator: Marcus Lee, MD
United States, Texas
Central Texas Clinical Research
Austin, Texas, United States, 78705
Contact:Principal Investigator: Cynthia Brinson, MD
Trinity Universal Research Associates, Inc.
Carrollton, Texas, United States, 75007
Contact:Principal Investigator: John Joseph, MD
Dallas Diabetes and Endocrine Center
Dallas, Texas, United States, 75230
Contact:Principal Investigator: Julio Rosenstock, MD
Research Institute of Dallas
Dallas, Texas, United States, 75231
Contact:Principal Investigator: Stephen L Aronoff, MD
Galenos Research
Dallas, Texas, United States, 75251
Contact:Principal Investigator: Rafael Canadas, MD
Pioneer Research Solutions, Inc.
Houston, Texas, United States, 77036
Contact:Principal Investigator: Subodh Bhuchar, MD
Centex Studies, Inc.
Houston, Texas, United States, 77058
Contact:Principal Investigator: Joe Pouzar, MD
Clinical Trial Network - Houston
Houston, Texas, United States, 77074
Contact:Principal Investigator: Ranjan Shah, MD
Juno Research, LLC-Houston
Houston, Texas, United States, 77074
Contact:Principal Investigator: Audrey Lacour, MD
Juno Research, LLC-Katy
Katy, Texas, United States, 77450
Contact:Principal Investigator: Hugo Toro, MD
Consano Clinical Research
San Antonio, Texas, United States, 78205
Contact:Principal Investigator: Michelle Welch, MD
Texas Diabetes Institute Research Center
San Antonio, Texas, United States, 78207
Contact:Principal Investigator: Ralph DeFronzo, MD
Sun Research Institute
San Antonio, Texas, United States, 78215
Contact:Principal Investigator: David Grant, MD
Victorium Clinical Research
San Antonio, Texas, United States, 78231
Contact:Principal Investigator: Jennefer Sutton, MD
Southwest Health Associates, P.A.
Sugarland, Texas, United States, 77478
Contact:Principal Investigator: Syed M Zaidi, MD
United States, Utah
Chrysalis Clinical Research
St. George, Utah, United States, 84790
Contact:Principal Investigator: Jonathan Hubbard, DO
United States, Virginia
Burke Internal Medicine & Research
Burke, Virginia, United States, 22015
Contact:Principal Investigator: Nashwa Gabra, MD
Manassas Clinical Research Center
Manassas, Virginia, United States, 20110
Contact:Principal Investigator: Nabil Andrawis, MD
National Clinical Research - Norfolk, Inc.
Norfolk, Virginia, United States, 23502
Clinical Research Partners, LLC
Richmond, Virginia, United States, 23235
Contact:Principal Investigator: Jospeh James, MD
United States, Washington
Universal Research Group, LLC
Tacoma, Washington, United States, 98405
Contact:Principal Investigator: Sabrina Benjamin, MD
Puerto Rico
Puerto Rico Renal and Health Research, Inc.
Carolina, Puerto Rico, 00987
Contact:Principal Investigator: Jose Ortiz-Rosario, MD
Advanced Medical Concepts
Cidra, Puerto Rico, 00736
Contact:Principal Investigator: Amaury Roman-Miranda, MD
Manati Center for Clinical Reserach Doctor's Center Hospital
Manati, Puerto Rico, 00674
Contact:Principal Investigator: Ramon Ortiz-Carrasquillo, MD
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services